World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
47
Citations
8823
World Ranking
4517
National Ranking
192

Paolo Airò publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Paolo Airò sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 227 publications — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Paolo Airò D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Paolo Airò sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 47 D-Index — 9th percentile

9% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Paolo Airò is affiliated with the University of Brescia in Italy and has a research focus primarily within the field of Medicine. Their work spans numerous specialized subfields including Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Epidemiology, Dermatology, and Rheumatology.

The scientist's research topics cover a range of clinical and biomedical areas. These include:

  • Systemic Sclerosis and Related Diseases
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Inflammatory Myopathies and Dermatomyositis
  • Dermatologic Treatments and Research
  • COVID-19 Clinical Research Studies
  • Inflammasome and Immune Disorders
  • Skin Diseases and Diabetes

Paolo Airò has contributed to several recent papers that address key medical challenges, particularly in rheumatology and pulmonary conditions. Selected recent publications include:

  • Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy (2020), published in Autoimmunity Reviews
  • Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database (2020), published in Annals of the Rheumatic Diseases
  • Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome (2020), published in Annals of the Rheumatic Diseases
  • COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study (2020), published in The Lancet Rheumatology
  • Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers (2022), published in Clinical Reviews in Allergy & Immunology

Frequent co-authors collaborating with Paolo Airò include:

  • Oliver Distler
  • Maria Grazia Lazzaroni
  • Franco Franceschini
  • Yannick Allanore
  • Marco Matucci-Cerinic

Paolo Airò's research appears regularly in established publication venues such as:

  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • Clinical and Experimental Rheumatology
  • The Lancet Rheumatology
  • Journal of Scleroderma and Related Disorders

Best Publications

  • Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

    Anthony J. Tyndall;Bettina Bannert;Madelon Vonk;Paolo Airò

  • Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.

    Paola Toniati;Simone Piva;Marco Cattalini;Emirena Garrafa

  • Mapping and predicting mortality from systemic sclerosis

    Muriel Elhai;Christophe Meune;Marouane Boubaya;Jérôme Avouac

  • Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group

    Jérôme Avouac;J. Fransen;U. A. Walker;V. Riccieri

  • Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

    Suzana Jordan;Jörg H W Distler;Britta Maurer;Dörte Huscher

  • Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus

    Timothy R.D.J. Radstake;Olga Y Gorlova;Blanca Rueda;Jose Ezequiel Martin

  • Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies

    Jérôme Avouac;Paolo Airò;Christophe Meune;Lorenzo Beretta

  • Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.

    Anna-Maria Hoffmann-Vold;Yannick Allanore;Margarida Alves;Cathrine Brunborg

  • Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis

    Y. Allanore;C. Meune;M. C. Vonk;P. Airo

  • Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study

    Veronika K. Jaeger;Elina G. Wirz;Yannick Allanore;Philipp Rossbach

  • Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis.

    Yannick Allanore;Yannick Allanore;Mohamad Saad;Philippe Dieudé;Jérôme Avouac;Jérôme Avouac

  • Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy

    Olga Gorlova;Jose Ezequiel Martin;Blanca Rueda;Bobby P C Koeleman

  • Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis

    Maureen D. Mayes;Lara Bossini-Castillo;Olga Gorlova;José Ezequiel Martin

  • Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study

    Muriel Elhai;Marine Meunier;Marco Matucci-Cerinic;Britta Maurer

  • Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study.

    Lorenzo Cavagna;Laura Nuño;Carlo Alberto Scirè;Marcello Govoni

  • Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

    Muriel Elhai;Marouane Boubaya;Oliver Distler;Vanessa Smith

  • The MUC5B Variant Is Associated with Idiopathic Pulmonary Fibrosis but Not with Systemic Sclerosis Interstitial Lung Disease in the European Caucasian Population

    Raphael Borie;Bruno Crestani;Philippe Dieude;Hilario Nunes

  • Digital ulcers predict a worse disease course in patients with systemic sclerosis.

    Carina Mihai;Robert Landewé;Désirée van der Heijde;Ulrich A Walker

  • Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.

    Mirko Scarsi;Silvia Piantoni;Enrico Colombo;Paolo Airó

  • Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms.

    Elisabetta Danieli;Paolo Airò;Lorenzo Bettoni;Massimo Cinquini

  • Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening.

    Maria-Grazia Lazzaroni;Ilaria Cavazzana;Enrico Colombo;Rucsandra Dobrota

  • COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study.

    Micaela Fredi;Ilaria Cavazzana;Liala Moschetti;Laura Andreoli

  • Systemic sclerosis: state of the art on clinical practice guidelines.

    Vanessa Smith;Vanessa Smith;Carlo Alberto Scirè;Rosaria Talarico;Paolo Airo

  • A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5

    Duilio Brugnoni;Paolo Airò;Giuseppe Rossi;Alessandra Bettinardi

  • Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study.

    Mara Taraborelli;Véronique Ramoni;Antonio Brucato;Paolo Airò

  • "High-dose" UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides.

    Cristina Zane;Carla Leali;Paolo Airò;Giuseppe De Panfilis

  • A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study

    Muriel Elhai;Jérôme Avouac;Ulrich A. Walker;Marco Matucci-Cerinic

  • Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial

    Piero Ruscitti;Francesco Masedu;Saverio Alvaro;Paolo Airò

Frequent Co-Authors

Yannick Allanore
Yannick Allanore Université Paris Cité
Angela Tincani
Angela Tincani University of Brescia
Franco Franceschini
Franco Franceschini University of Brescia
Marco Matucci-Cerinic
Marco Matucci-Cerinic University of Florence
Oliver Distler
Oliver Distler University of Zurich
Eric Hachulla
Eric Hachulla University of Lille
Valeria Riccieri
Valeria Riccieri Sapienza University of Rome
Ilaria Cavazzana
Ilaria Cavazzana University of Brescia
Gabriela Riemekasten
Gabriela Riemekasten University of Lübeck
Christopher P. Denton
Christopher P. Denton University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various healthcare careers, many of which offer flexible online education options. For those interested in entering nursing without prior experience, online ADN programs for non nurses provide a practical starting point. These programs accommodate beginners eager to build foundational nursing skills.

Accelerated paths are also available, especially for individuals seeking to transition quickly into registered nursing roles. Programs like absn programs with high acceptance rates offer an accessible route to earn a Bachelor of Science in Nursing, often designed to fit busy schedules.

For those considering practical nursing, exploring easy lpn programs to get into can help identify the most approachable options. These programs are typically shorter and can lead to valuable entry-level nursing roles, which can be a stepping stone towards specialization.

Advanced practice roles like nurse practitioners are critical in immunology-linked healthcare settings. Investigating easiest online nurse practitioner programs reveals convenient paths for nurses who wish to advance their credentials and impact patient care on a higher level.

Best Scientists Citing Paolo Airò

Trending Scientists

Recently Published Articles